Floatz logo

egf816

Advanced Hepatocellular Carcinoma

Novartis PharmaceuticalsSmall moleculePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
81/ 100

Competitive context

38 Active assets in the Advanced Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Penpulimab
West China Hospital
Phase 3BB
Octreotide Pamoate
Clinica Universidad de Navarra, Universidad de Navarra
Phase 3BB
Dfn-15
Emory University
Phase 4BB
Shr-8068
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3B
Serplulimab
Shanghai Henlius Biotech
Phase 3B

View all 50 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →